About: In vitro characterization of PrismaLung+: a novel ECCO(2)R device

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: In vitro characterization of PrismaLung+: a novel ECCO(2)R device Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	In vitro characterization of PrismaLung+: a novel ECCO(2)R device
Creator	Laffey, John Goldstein, Jacques Harenski, Kai Hospach, Ingeborg Pouchoulin, Dominique Raible, Manuela Storr, Markus Votteler, Stefanie
Source	PMC
abstract	BACKGROUND: Invasive mechanical ventilation is lifesaving in the setting of severe acute respiratory failure but can cause ventilation-induced lung injury. Advances in extracorporeal CO(2) removal (ECCO(2)R) technologies may facilitate more protective lung ventilation in acute respiratory distress syndrome, and enable earlier weaning and/or avoid invasive mechanical ventilation entirely in chronic obstructive pulmonary disease exacerbations. We evaluated the in vitro CO(2) removal capacity of the novel PrismaLung+ ECCO(2)R device compared with two existing gas exchangers. METHODS: The in vitro CO(2) removal capacity of the PrismaLung+ (surface area 0.8 m(2), Baxter) was compared with the PrismaLung (surface area 0.35 m(2), Baxter) and A.L.ONE (surface area 1.35 m(2), Eurosets) devices, using a closed-loop bovine blood–perfused extracorporeal circuit. The efficacy of each device was measured at varying pCO(2) inlet (p(in)CO(2)) levels (45, 60, and 80 mmHg) and blood flow rates (Q(B)) of 200–450 mL/min; the PrismaLung+ and A.L.ONE devices were also tested at a Q(B) of 600 mL/min. The amount of CO(2) removed by each device was assessed by measurement of the CO(2) infused to maintain circuit equilibrium (CO(2) infusion method) and compared with measured CO(2) concentrations in the inlet and outlet of the CO(2) removal device (blood gas analysis method). RESULTS: The PrismaLung+ device performed similarly to the A.L.ONE device, with both devices demonstrating CO(2) removal rates ~ 50% greater than the PrismaLung device. CO(2) removal rates were 73 ± 4.0, 44 ± 2.5, and 72 ± 1.9 mL/min, for PrismaLung+, PrismaLung, and A.L.ONE, respectively, at Q(B) 300 mL/min and p(in)CO(2) 45 mmHg. A Bland–Altman plot demonstrated that the CO(2) infusion method was comparable to the blood gas analysis method for calculating CO(2) removal. The resistance to blood flow across the test device, as measured by pressure drop, varied as a function of blood flow rate, and was greatest for PrismaLung and lowest for the A.L.ONE device. CONCLUSIONS: The newly developed PrismaLung+ performed more effectively than PrismaLung, with performance of CO(2) removal comparable to A.L.ONE at the flow rates tested, despite the smaller membrane surface area of PrismaLung+ versus A.L.ONE. Clinical testing of PrismaLung+ is warranted to further characterize its performance.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1186/s40635-020-00301-7
bibo:pmid	32405714
has license	cc-by
sha1sum (hex)	82367716d23616e119df1682e2fb8c00f674cd91
schema:url	https://doi.org/10.1186/s40635-020-00301-7
resource representing a document's title	In vitro characterization of PrismaLung+: a novel ECCO(2)R device
has PubMed Central identifier	PMC7221037
has PubMed identifier	32405714
schema:publication	Intensive Care Med Exp
resource representing a document's body	covid:82367716d23616e119df1682e2fb8c00f674cd91#body_text
is schema:about of	named entity 'VENTILATION' named entity 'BACKGROUND' named entity 'PCO' named entity '28P' named entity '600' named entity 'BOVINE' named entity '50%' named entity 'LOWEST' named entity 'DEMONSTRATED' named entity 'PERFORMANCE' named entity 'GREATEST' named entity 'OF EACH' named entity 'EARLIER' named entity 'EQUILIBRIUM' named entity 'mmHg' named entity 'perfused' named entity 'flow rates' named entity 'chronic obstructive pulmonary disease' named entity 'blood gas analysis' named entity 'Clinical testing' named entity 'surface area' named entity 'weaning' named entity 'blood flow' named entity 'surface area' named entity 'Switzerland' named entity 'extracorporeal' named entity 'coagulation' named entity 'blood flow' named entity 'ECMO' named entity 'Germany' named entity 'continuous renal replacement' named entity 'risk/benefit ratio' named entity 'acute lung injury' named entity 'ARDS' named entity 'hypercapnic' named entity 'blood gas analysis' named entity 'gas exchange' named entity 'mmol' named entity 'IMV' named entity 'organ support' named entity 'mmol' named entity 'AKI' named entity 'infusion' named entity 'blood gas analysis' named entity 'blood flow' named entity 'blood flow' named entity 'Blood samples' named entity 'ARDS' named entity 'continuous renal replacement therapy' named entity 'infusion' named entity 'atmospheric pressure' named entity 'aeCOPD' named entity 'surface area' named entity 'mmHg' named entity 'extracorporeal' named entity '1 mL' named entity '49, 50' named entity 'normal distribution' named entity 'blood gas' named entity 'ventilatory support' named entity 'respiratory failure' named entity 'LPV' named entity 'hypoxemic' named entity 'infusion' named entity 'mechanical ventilation' named entity 'positive end-expiratory pressure' named entity 'mmHg' named entity 'mmHg' named entity 'NaCl' named entity 'ECMO' named entity 'thermostat' named entity 'volume flow' named entity 'surface area' named entity 'infusion'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software